Zoetis (NYSE:ZTS) PT Raised to $225.00

Zoetis (NYSE:ZTS) had its price objective lifted by BTIG Research from $220.00 to $225.00 in a research report report published on Monday, Benzinga reports. BTIG Research currently has a buy rating on the stock.

ZTS has been the subject of a number of other reports. Stifel Nicolaus boosted their target price on shares of Zoetis from $180.00 to $200.00 and gave the stock a buy rating in a research note on Monday, August 5th. HSBC reduced their price objective on Zoetis from $230.00 to $225.00 and set a buy rating on the stock in a report on Wednesday, May 8th. Piper Sandler reissued an overweight rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group decreased their price target on Zoetis from $223.00 to $196.00 and set a buy rating on the stock in a report on Monday, May 6th. Finally, Barclays dropped their price objective on Zoetis from $260.00 to $230.00 and set an overweight rating for the company in a report on Tuesday, April 23rd. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of Buy and an average price target of $217.11.

Zoetis Price Performance

Shares of Zoetis stock opened at $184.08 on Monday. Zoetis has a 1-year low of $144.80 and a 1-year high of $201.92. The firm’s 50-day moving average price is $177.64 and its two-hundred day moving average price is $175.38. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $83.40 billion, a price-to-earnings ratio of 35.47, a P/E/G ratio of 2.81 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $1.41 EPS. On average, equities analysts predict that Zoetis will post 5.84 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Institutional Trading of Zoetis

Several hedge funds have recently bought and sold shares of ZTS. Webster Bank N. A. grew its holdings in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares in the last quarter. Private Wealth Management Group LLC bought a new position in Zoetis during the fourth quarter worth about $33,000. Gladius Capital Management LP acquired a new position in Zoetis during the fourth quarter worth approximately $40,000. Neo Ivy Capital Management acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $40,000. Finally, LRI Investments LLC bought a new stake in Zoetis in the 1st quarter valued at $43,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.